Side-by-side · Research reference
CrystagenvsHumanin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED12/40 cited
BAnimal-StrongHUMAN-REVIEWED14/52 cited
Crystagen
Khavinson Bioregulator · Immune-Thymic
SQ · Protocol variable
Humanin
Mitochondrial-Derived Peptide · Cytoprotective
SQ · Experimental
01Mechanism of Action
Parameter
Crystagen
Humanin
Primary target
B-lymphocytes in splenic tissueСhervyakova 2014
Pathway
B-cell activation → Immune modulation during agingСhervyakova 2014
Humanin binds Bax/Bim → inhibits mitochondrial outer membrane permeabilization (MOMP) → blocks cytochrome c release → prevents caspase activation → cell survival
Downstream effect
B-cell activation via apoptosis reduction; no observed increase in splenic cell renewalСhervyakova 2014
Suppression of apoptosis, mitochondrial stabilization, reduced oxidative stress, preservation of germ cells and neurons under stressZhu 2022Lue 2021Velentza 2024
Feedback intact?
Unknown — bioregulator mechanism not fully characterized
Not applicable — peptide acts as anti-apoptotic signal, not hormonal axis
Origin
Synthetic Lys-Glu-Asp-Gly tetrapeptide — Khavinson bioregulator series
Encoded by short open reading frame in mitochondrial 16S rRNA gene (MTRNR2). 24-28 amino acids. 13 homologous variants (MTRNR2L1-L13) identified.Zhu 2022Shahzaib 2026
Antibody development
—
Not reported in animal models
02Dosage Protocols
Parameter
Crystagen
Humanin
Standard dose
Not standardized — variable protocols
Russian bioregulator literature does not specify unified human dosing.
—
Route
Subcutaneous (presumed from bioregulator class)
—
Frequency
Unknown — bioregulator protocols variable
Daily (IP)
Duration
Unknown — chronic administration presumed in animal models
8–12 weeks in animal studies
Half-life
Not reported
—
Standard experimental dose (HNG)
—
4 mg/kg IP (rat)
Most common dose in rodent models.
Ex vivo bone culture
—
1 µg/mL
Protective against venetoclax-induced bone growth retardation.
Human data
—
None — no clinical trials reported
Analog (HNG)
—
Gly[14]-humanin — more potent variant
Substitution at position 14 enhances cytoprotective activity.
03Metabolic / Fat Loss Evidence
Parameter
Crystagen
Humanin
Direct fat loss evidence
—
None
Mechanism overlap
—
Mitochondrial health may indirectly influence metabolic efficiency, but no quantified effect
04Side Effects & Safety
Parameter
Crystagen
Humanin
Published adverse events
None reported in available animal literature
—
Human safety data
Absent — no controlled human trials identified
None — no clinical trials
Autoimmune considerations
Theoretical concern with B-cell modulators in predisposed individuals
—
Animal model safety
—
Well-tolerated in rat and mouse studies at 4 mg/kg for 8–12 weeks
Theoretical fibrillation risk
—
Induces amyloid-like fibrillation of Bax/BID. Long-term sequelae unknown.
Injection site reaction
—
Not reported in animal studies (IP route)
Reproductive safety
—
Protective in POI model (cyclophosphamide-induced), no adverse effects on fertility notedHuang 2025
Absolute Contraindications
Crystagen
- ·Active autoimmune disease (theoretical)
Humanin
- ·Unknown — no human data
Relative Contraindications
Crystagen
- ·Pregnancy / lactation (no data)
- ·Active B-cell malignancies
Humanin
- ·Active malignancy (theoretical risk of anti-apoptotic effect on tumour cells)
05Administration Protocol
Parameter
Crystagen
Humanin
1. Route
Subcutaneous injection — presumed from bioregulator class convention. Specific anatomical sites not standardized.
Intraperitoneal (IP) in animal models. Subcutaneous route untested. No human protocols exist.
2. Reconstitution
Protocol not standardized. If lyophilized, sterile water or bacteriostatic saline typical for peptide bioregulators.
Synthetic peptide reconstituted in sterile saline or PBS. No commercial formulation available.
3. Timing
Not specified. Bioregulator protocols vary — some practitioners advocate evening dosing, others morning.
Daily administration in animal studies. Optimal timing not characterized.
4. Storage
Lyophilized: room temperature, light-protected. Reconstituted: refrigerate, use within days to weeks depending on preservative.
Lyophilised powder: -20 °C. Reconstituted: 4 °C, use within 7 days. Avoid freeze-thaw cycles.
5. Human use
—
No FDA approval, no IND, no clinical trials. Experimental research tool only.
06Stack Synergy
Crystagen
+ Vilon
Multi-pathwayVilon (Lys-Glu) activates T-helper cells via apoptosis reduction, while Crystagen activates B-cells. Dual T/B immune modulation in aging models may provide complementary thymic-immune support within the Khavinson bioregulator framework. Both target splenic immune aging through distinct lymphocyte subsets.
- Crystagen
- Dose unknown · SQ
- Vilon
- Dose unknown · SQ
- Frequency
- Protocol variable
- Primary benefit
- Broader thymic-immune coverage (T-cell + B-cell)
Humanin
+ MOTS-c
Multi-pathwayBoth are mitochondrial-derived peptides. MOTS-c enhances metabolic efficiency and insulin sensitivity via AMPK activation, while humanin prevents mitochondrial apoptosis. Combined, they address mitochondrial function (MOTS-c) and survival signaling (humanin), supporting cellular resilience under metabolic and oxidative stress.
- Humanin
- 4 mg/kg IP · daily (animal model)
- MOTS-c
- 5 mg/kg IP · daily (animal model)
- Frequency
- Once daily
- Primary benefit
- Mitochondrial health, metabolic efficiency, anti-apoptotic signaling